US Thematic Research "UBS Evidence Lab inside: UBS Private Market Monitor ..."

Research evidence excerpt

US Thematic Research "UBS Evidence Lab inside: UBS Private Market Monitor ..."

Powered by Lab Global12 MayResearch2026ab Evidence UBS YES

US Thematic Research Equities

AmericasUBS Evidence Lab inside: UBS Private Market

Monitor - Keeping Up with Private Capital Healthcare

Samantha Meadows, PhD

Analyst

samantha.meadows@ubs.com

We highlight relevant UBS research and the latest trends in VC/PE. This week +1-212-713 2482

we include details on the latest biopharma M&A activity and the executive

Angela Kumirai

order + priority review vouchers to accelerate psychedelic drug treatments.

Associate Analyst

Inside the report, we include links to UBS’s most recently published private company angela.kumirai@ubs.com

profiles, the latest news on potential upcoming IPOs, the latest financing rounds/sector +1-212-713 1266

level investment trends, and other news we are watching. We also include our takes on

recent UBS research that we think have implications for private markets, upcoming

UBS ARC events, and upcoming UBS events with private companies in attendance.

See below for a detailed overview of what is inside the report:

1. Recent private company reports from UBS research:

a. FinTech: Getnet,Infinicept, MOOV,Revolut,Run Payments, OpenFX,

Rainforest, Firmly

b. Healthcare:

i. Non-Therapeutics:10X Health Systems, AffirmedRx, AGED Diagnostics,

Anterior, Contraline, DeepScribe AI, Everly Health, Evvy, Heartland Dental,

Hippocratic AI, Judi Health, Kindbody, Longitude Health, Lungpacer

Medical, Midi Health, North American Dental Group,

Pacific Dental Services, Paytient, Pearl Health, Personify Health, PostEra,

Renalogic, Smile Brands, Specialty Care, Tia Health, Thyme Care, Visana

Health, Vvardis, Wellvana

i. Biotech: Adscendo, Bambusa Therapeutics, Caldera Therapeutics, Calissa